Advanced healthcare materials · 2026
NIR-Triggered Organic Semiconductor Bulk Heterostructure Nanoparticles Enable Dual-Mechanism Photodynamic Anti-Tumor Therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Ying, Ma Shida, He Yongrui, Yue Yuchen, Qiao Zihan, Zeng Landi, Wang Yaru, Wang Ying-Shuai, Qi Li, Zhou Jin, Wang Bin, Zheng Bing
Аннотация
Low-bandgap non-fullerene acceptors (NFAs) predominantly generate a variety of reactive oxygen species (ROS) via the type-I photodynamic process, a feature that renders them particularly advantageous for the treatment of hypoxic solid tumors. However, the hypoxic microenvironment typically arises during type-I PDT can upregulate apoptosis-suppressing genes and promote immunosuppression, thereby facilitating tumor cell survival, invasion, and metastasis. To address these limitations, we integrated the charge-transport material PFN-Br with an NFA (H1) to construct bulk heterostructured nanoparticles (H2 (10:1)@NPs). This structural design not only promoted J-aggregation of H2-NPs, but also enhanced their spin-orbit coupling (SOC) through the external heavy-atom effect, thereby facilitating efficient intersystem crossing (ISC) from the singlet excited state (S1) to the triplet state (T1). The resulting increase in the T1 exciton augmented both charge and energy transfer, leading to a marked enhancement in type-I and type-II ROS production. Consequently, PFN-Br as ROS amplifier within the bulk heterostructure, disrupting intracellular redox homeostasis and activating both apoptotic and pyroptotic cell death pathways to achieve pronounced antitumor efficacy. This study offers new strategic insights for advancing high-performance photocatalytic tumor therapy toward clinical application.